Morgan Stanley reissued their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report issued on Wednesday morning, Stock Target Advisor reports.
A number of other research firms also recently weighed in on HIK. Peel Hunt reissued a hold rating on shares of Hikma Pharmaceuticals in a report on Monday, November 4th. Citigroup reissued a buy rating on shares of Hikma Pharmaceuticals in a report on Thursday, November 7th. Finally, Barclays increased their target price on Hikma Pharmaceuticals from GBX 1,800 ($23.52) to GBX 1,900 ($24.83) and gave the company an equal weight rating in a report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of GBX 1,781.67 ($23.28).
Shares of LON:HIK traded up GBX 12 ($0.16) during midday trading on Wednesday, reaching GBX 1,889 ($24.68). 293,958 shares of the company’s stock traded hands, compared to its average volume of 822,138. The company has a market cap of $4.58 billion and a price-to-earnings ratio of 12.69. The company has a debt-to-equity ratio of 37.69, a quick ratio of 0.78 and a current ratio of 1.28. Hikma Pharmaceuticals has a one year low of GBX 1,491.50 ($19.49) and a one year high of GBX 2,212 ($28.90). The stock has a 50 day moving average of GBX 2,017.85 and a 200 day moving average of GBX 1,867.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.